Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland.
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Ophthalmology. 2024 Jan;131(1):78-86. doi: 10.1016/j.ophtha.2023.08.021. Epub 2023 Aug 25.
To compare rates of diagnosis of neuro-ophthalmic conditions across the Coronavirus Disease 2019 (COVID-19) pandemic with pre-pandemic levels.
Multicenter, retrospective, observational study.
Patients seen for eye care between March 11, 2019, and December 31, 2021.
A multicenter electronic health record database, Sight Outcomes Research Collaborative (SOURCE), was queried for new diagnoses of neuro-ophthalmic conditions (cranial nerve [CN] III, IV, VI, and VII palsy; diplopia; and optic neuritis) and new diagnoses of other ophthalmic conditions from January 1, 2016, to December 31, 2021. Data were divided into 3 periods (pre-COVID, pre-COVID vaccine, and after introduction of COVID vaccine), with a 3-year look-back period. Logistic regressions were used to compare diagnosis rates across periods. Two-sample z-test was used to compare the log odds ratio (OR) of the diagnosis in each period with emergent ocular conditions: retinal detachment (RD) and acute angle-closure glaucoma (AACG).
Diagnosis rate of neuro-ophthalmic conditions in each study period.
A total of 323 261 unique patients (median age 59 years [interquartile range, 43-70], 58% female, 68% White) across 5 academic centers were included, with 180 009 patients seen in the pre-COVID period, 149 835 patients seen in the pre-COVID vaccine period, and 164 778 patients seen in the COVID vaccine period. Diagnosis rates of CN VII palsy, diplopia, glaucoma, and cataract decreased from the pre-COVID period to the pre-vaccine period. However, the optic neuritis diagnoses increased, in contrast to a decrease in RD diagnoses (P = 0.021). By comparing the diagnosis rates before and after widespread vaccination, all eye conditions evaluated were diagnosed at higher rates in the COVID vaccination period compared with pre-COVID and pre-vaccine periods. The log OR of neuro-ophthalmic diagnosis rates across every period comparison were largely similar to emergency conditions (RD and AACG, P > 0.05). However, the log OR of cataract and glaucoma diagnoses were different to RD or AACG (P < 0.05) in each period comparison.
Neuro-ophthalmic diagnoses had a similar reduction in diagnosis rates as emergent eye conditions in the first part of the pandemic, except optic neuritis. After widespread COVID-19 vaccination, all ophthalmic diagnosis rates increased compared with pre-pandemic rates, and the increase in neuro-ophthalmic diagnosis rates did not exceed the increase in RD and AACG diagnosis rates.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
比较 2019 年冠状病毒病(COVID-19)大流行期间与流行前水平的神经眼科疾病的诊断率。
多中心、回顾性、观察性研究。
2019 年 3 月 11 日至 2021 年 12 月 31 日期间因眼部护理就诊的患者。
多中心电子健康记录数据库 Sight Outcomes Research Collaborative (SOURCE) 对新诊断的神经眼科疾病(颅神经 [CN] III、IV、VI 和 VII 麻痹;复视;和视神经炎)和新诊断的其他眼科疾病进行了查询从 2016 年 1 月 1 日至 2021 年 12 月 31 日。数据分为 3 个时期(COVID 前、COVID 疫苗前和 COVID 疫苗引入后),并进行了 3 年的回顾期。使用逻辑回归比较各期的诊断率。两样本 z 检验用于比较每个时期与紧急眼部疾病(视网膜脱离 [RD] 和急性闭角型青光眼 [AACG])的诊断的对数优势比(OR)。
各研究期神经眼科疾病的诊断率。
在 5 个学术中心共纳入 323261 名(中位年龄 59 岁 [四分位距,43-70],58%为女性,68%为白人)的独特患者,其中 COVID 前时期有 180009 名患者,COVID 疫苗前时期有 149835 名患者,COVID 疫苗时期有 164778 名患者。从 COVID 前时期到 COVID 疫苗前时期,CN VII 麻痹、复视、青光眼和白内障的诊断率下降。然而,视神经炎的诊断有所增加,而 RD 的诊断则有所下降(P=0.021)。通过比较广泛接种疫苗前后的诊断率,与 COVID 前和 COVID 疫苗前时期相比,评估的所有眼部疾病在 COVID 疫苗接种期间的诊断率均更高。在每个时期的比较中,神经眼科诊断率的对数 OR 与紧急情况(RD 和 AACG,P>0.05)基本相似。然而,在每个时期的比较中,白内障和青光眼的诊断率对数 OR 与 RD 或 AACG 不同(P<0.05)。
在大流行的第一阶段,神经眼科诊断率与紧急眼部疾病一样出现了类似的下降,除了视神经炎。在 COVID-19 广泛接种疫苗后,与大流行前相比,所有眼部诊断率均有所增加,神经眼科诊断率的增加并未超过 RD 和 AACG 诊断率的增加。
本文末尾的脚注和披露中可能存在专有或商业披露。